BioSpace News Archive

Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, will participate in two upcoming healthcare conferences.

Newtopia Inc. (“Newtopia” or the “Company”) (TSXV: NEWU) (OTCQB: NEWUF), a tech-enabled whole health platform creating sustainable habits that prevent, slow, and reverse chronic disease, today announced that on September 14, 2022, at the Company’s annual and special meeting of shareholders (the “Meeting”).

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 901,950 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Titan Medical Inc. announced the publication of international patent application No. PCT/CA2022/050392, which the company anticipates pursuing in the United States and other key markets under the Patent Cooperation Treaty.

Precision Optics Corporation, Inc. (OTCQB: PEYE) (the “Company”) today announced that it has scheduled a conference call to discuss its fiscal year 2022 financial results on Tuesday, September 27, 2022, at 5:00pm ET.

NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results for half-year ending June 30, 2022, on Wednesday, September 28, 2022, after the close of the US market.

NovaBay® Pharmaceuticals, Inc. announces that Chief Executive Officer Justin Hall has issued the following Letter to Stockholders: To My Fellow Stockholders: Over the past year, we have successfully transformed NovaBay from a single product company into a larger organization with three brands in three distinct market segments.

Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”) today announced that it will effect a 1-for-15 reverse split of its common stock, which will be effective for trading purposes on the Nasdaq Capital Market as of the commencement of trading on September 23, 2022, and also provided a regulatory update related to its intravenous (“IV”) Tramadol product candidate.

Scholar Rock, a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role announced that the company granted equity awards as a material inducement to an employee hired by Scholar Rock in September 2022.

Mutations can be good and bad. Sometimes they help an organism adapt and survive.